Other Biopharmaceuticals

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

SBFMW

SBFM

LABU

SBIO

Sunshine Biopharma Inc. has priced a $6 million public offering, consisting of 12 million common units at $0.50 each, sending shares up 79.51% to $0.51. The offering includes Series C warrants exercisable at $0.50 for five years. Proceeds will support corporate purposes and working capital. The company markets 60 generic drugs in Canada and plans to launch 12 more in 2026, while advancing proprietary programs targeting oncology and SARS-related coronaviruses.

nasdaq

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

VG Health

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Nasdaq

Sunshine Biopharma Prices $6M Offering; Closing May 19

U.S. stocks fell, with the Nasdaq down 200 points, Dow down 0.04%, and S&P 500 down 0.37%. Energy shares rose 1.8%, while tech stocks dropped 1.6%. Brady Corporation reported strong Q1 earnings, with EPS of $1.50, exceeding estimates. Sunshine Biopharma surged 349%, while AiRWA fell 28%. Oil prices increased by 1.4%, and European markets showed gains.

benzinga_article

Brady

NASDAQ Composite Index

Dow Jones Industrial Average

S&P 500

AiRWA

Aditxt

Design Therapeutics

Hang Seng Index

SSE Index

Nasdaq Down 200 Points; Brady Earnings Top Views

Sunshine Biopharma (SBFM) stock surged 561.74% in premarket trading despite no new news or events. The company has a low float of 4.9 million shares and experienced heavy trading with 225 million shares exchanged, indicating a potential stock squeeze. However, SBFM has a history of stock reverse splits, raising concerns for investors. Year-to-date, the stock has fallen 76.9% and 80.93% over the past year.

Tip Ranks

iShares Global Healthcare

Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?

RAMP

LiveRamp Holdings Inc (NYSE: RAMP) shares surged over 26% in pre-market trading following its acquisition by Publicis for $2.2 billion. The deal values LiveRamp at $38.50 per share. The company also reported better-than-expected Q4 earnings, with earnings of 52 cents per share and sales of $206.092 million. Other notable pre-market movers included Sunshine Biopharma Inc (SBFM) up 182.4% and Bitcoin Depot Inc (BTM) down 73.7% due to bankruptcy filing.

Bitcoin Depot

LiveRamp

Smart Powerr

Picard Medical

DirectBooking Tech

Compass Pathways

Destiny Tech100

Edible Garden AG

P3 Health Partners

Artelo Biosciences

HCW Biologics

Amaze

Dreamland

Haoxi Health Tech

Regeneron Pharma

Li Auto

LI AUTO-W

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

GCT SEMICONDUCTOR HOLDING INC C/WTS 01/03/2029(TO PUR COM)

BITCOIN DEPOT INC C/WTS 30/06/2028(TO PUR COM)

EDIBLE GARDEN AG INC C/WTS (TO PUR COM)

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Sunshine Biopharma Inc. (NASDAQ:SBFM) has announced the pricing of a public offering expected to raise approximately $6.0 million. The offering includes 12,000,000 Common Units priced at $0.50 each, consisting of shares and warrants. The transaction is anticipated to close around May 19, 2026, subject to customary conditions. Proceeds will be used for general corporate purposes. Aegis Capital Corp. is the exclusive placement agent for the offering.

StockTitan

Direxion S&P Biotech Bear 3X

Ark Genomic Revolution ETF

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering | SBFM Stock News

SBFM (Sunshine Biopharma Inc.) is set to announce its Q1'26 results on May 13, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 9.20 million USD with EPS (earnings per share) anticipated at (0.16) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported8.90 M9.41 M9.42 M8.58 M—Revenue Estimate—11.20 M11.10 M10.00 M9.20 MRevenue Surprise-15.98%-15.16%-14.23%EPS Reported(0.44)(0.39)(0.19)(0.30) EPS Estimate(0.11)(0.13)(0.27)(0.16) EPS Surprise-254.55%-46.15%-11.11%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

TradingView

SBFM Q1'26 Earnings: EPS estimate is (0.16) USD

Kunal Dhamesha, Senior Analyst at Macquarie Capital, says Sun Pharma’s U.S. acquisition could encourage its peers to look beyond generics and pursue M&As in specialty and patented medicines, though appetite will vary by company strategy, R&D depth and risk tolerance.

Macquarie Group Limited

How Sun Pharma’s US buy could spur other Indian pharma firms' global expansion

Sunshine Biopharma Posts Modest 2025 Revenue Growth and Tightens Costs to Pursue Profitability